Aegis Capital raised its price target on Inovio Pharmaceuticals (NASDAQ: INO) to $14.00 (from $11.00) while maintaining a Buy rating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

UPDATE: Inovio Pharmaceuticals (INO) PT Raised to $12 at Maxim Group; 'A Step Closer to HIV Vaccine, PENNVAX-GP Demonstrates High Immune Response Rates'May 24, 2017 2:29 PM Inovio Pharma (INO) Data Reported Was Positive, "Terrific Vaccine in a World of Unknowns" - StifelMay 24, 2017 11:08 AM Pre-Open Stock Movers 05/24: (INO) (TCS) (TLYS) Higher; (ANW) (DY) (CHS) Lower (more...)May 24, 2017 9:27 AM Inovio Pharma (INO) Says HIV Vaccine Elicits Nearly 100% Immune Response Rates in StudyMay 24, 2017 8:18 AM Inovio HIV Vaccine Elicits Nearly 100% Immune Response Rates in a Clinical StudyMay 24, 2017 8:01 AM